Allergy & Immunology

Immunogenomics

Submit Abstract Register Now

Immunogenomics originally was framed by research supporting the hypothesis that cancer mutations generated novel peptides seen as ‘‘non-self’’ by the immune system. ‘Neoantigens’ has been facilitated by the combination of specialized computational analyses, new sequencing technologies, and HLA binding predictions that evaluate somatic alterations in a cancer genome and interpret their ability to produce an immune-stimulatory peptide. The resulting information can characterize a tumor’s Neoantigens load, its cadre of infiltrating immune cell types, the T or B cell receptor repertoire, and direct the design of a personalized therapeutic.